People | Locations | Statistics |
---|---|---|
Naji, M. |
| |
Motta, Antonella |
| |
Aletan, Dirar |
| |
Mohamed, Tarek |
| |
Ertürk, Emre |
| |
Taccardi, Nicola |
| |
Kononenko, Denys |
| |
Petrov, R. H. | Madrid |
|
Alshaaer, Mazen | Brussels |
|
Bih, L. |
| |
Casati, R. |
| |
Muller, Hermance |
| |
Kočí, Jan | Prague |
|
Šuljagić, Marija |
| |
Kalteremidou, Kalliopi-Artemi | Brussels |
|
Azam, Siraj |
| |
Ospanova, Alyiya |
| |
Blanpain, Bart |
| |
Ali, M. A. |
| |
Popa, V. |
| |
Rančić, M. |
| |
Ollier, Nadège |
| |
Azevedo, Nuno Monteiro |
| |
Landes, Michael |
| |
Rignanese, Gian-Marco |
|
Rodrigues, Robim
Vrije Universiteit Brussel
in Cooperation with on an Cooperation-Score of 37%
Topics
Publications (2/2 displayed)
Places of action
Organizations | Location | People |
---|
document
Differentiation of multipotent human skin-derived precursors towards hepatic stellate cell-like cells for modelling liver fibrosis in vitro
Abstract
Recently, our group showed that hepatic progenitor-like cells derived from multipotent human skin-derived precursors (hSKPs) are valuable for testing of hepatocyte-specific anti-NASH effects of PPAR agonists. However, advanced NASH is often associated with the development of liver fibrosis, a process in which hepatic stellate cells (HSCs) play a pivotal role. Yet, testing of anti-fibrotic drugs is hampered by a lack of adequate human-relevant preclinical models. Here, we apply a publicly available protocol for generation of HSC-like cells from induced pluripotent stem cells (Coll et al. 2018) on hSKPs to differentiate these cells towards hepatic stellate cell-like cells (hSKP-HSCs). Further, we investigate whether the obtained cells can be activated and if these cells respond to the PPAR-α/δ agonist elafibranor. <br/>According to the protocol of Coll et al., hSKPs were sequentially exposed in vitro to BMP4, FGF1, FGF3 (all 20 ng/ml), retinol (5 µM) and palmitic acid (100 µM) for 12 days, rendering hSKP-HSCs. At the end of the differentiation, hSKP-HSCs were exposed for 24 hours to TGF-β (10 ng/ml) with and without elafibranor at subcytotoxic concentration (30 µM). Expression of HSC markers was measured using RT-qPCR and compared to levels in the commercially available human immortalized hepatic stellate cell line LX-2. Protein expression was evaluated using immunocytochemistry.<br/>Differentiation results in star-shaped cells and upregulation of the submesothelial HSC-progenitor marker ALCAM and also of key genes involved in intermediate filament formation (DES) and vitamin A metabolism (LRAT) to levels approaching or exceeding those in LX-2 cells. In addition, hSKP-HSCs express PDGFRβ, a membrane marker of HSCs. Activation of hSKP-HSCs by TGF-β could be demonstrated by upregulation of pro-fibrotic genes ACTA2, COL1A1 and LOXL2. As proof-of-principle, concomitant exposure to elafibranor leads to repression of the aforementioned genes.<br/>In conclusion, hSKPs hold potential to differentiate towards HSC-like cells, expressingspecific HSC markers. Upregulation of activation markers upon exposure to TGF-β indicates that hSKP-HSCs respond to pro-fibrotic stimuli. Furthermore, the activated hSKP-HSCs respond to elafibranor, suggesting future possibilities for preclinical drug testing. Nevertheless, further in-depth characterization of hSKP-HSCs is necessary.<br/>